NCT00439426View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Nasopharyngeal Cancer

Interventions

DRUG

Oxaliplatin

130mg/m2 iv on day 1 of each 3 week cycle

DRUG

capecitabine [Xeloda]

1000mg/m2 po bid on days 1-14 of each 3 week cycle

Trial Locations (5)

6213

Rabat

10000

Rabat

20502

Casablanca

40000

Marrakesh

80000

Agadir

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00439426 - A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer. | Biotech Hunter | Biotech Hunter